USP9X stabilizes and deubiquitinates β-catenin by removing the Lys 48-linked polyubiquitin chains that mark it for proteasomal degradation, thereby promoting glioma cell proliferation and survival and indicating it as a therapeutic target in high-grade gliomas [99]. The gene discussed is USP9X; the disease is central nervous system cancer.